{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:24:48Z","timestamp":1784546688587,"version":"3.55.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands are a novel class of radiopharmaceuticals developed for potential theranostic application in prostate cancer (PCa). We aimed to consolidate existing evidence on utility of <jats:sup>18<\/jats:sup>F-rhPSMA-7\/7.3 for PET imaging in PCa in the setting of biochemical recurrence (BCR).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods:<\/jats:title>\n            <jats:p>A comprehensive literature search was performed using relevant keywords in PubMed, Scopus, and EMBASE. Articles evaluating utility of <jats:sup>18<\/jats:sup>F-rhPSMA-7\/7.3 PET in PCa BCR, published through September 30, 2024, were included. rhPSMA PET detection rate (DR) in BCR was calculated on a per-patient basis, with pooled proportion and 95% confidence interval. Furthermore, pooled DRs using different cutoff values of serum prostate-specific antigen (PSA) were obtained.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Five studies with 1513 patients (overall) were included. The pooled DR of <jats:sup>18<\/jats:sup>F-rhPSMA-7\/7.3 PET in BCR was 81.7% (95% confidence interval: 76.3%\u201386.5%). The pooled DRs stratified by serum PSA levels were 60.7% for PSA &lt;0.5\u00a0ng\/mL, 80.1% for PSA between 0.5 and &lt;1.0\u00a0ng\/mL, 85.9% for PSA between 1.0 and &lt;2.0\u00a0ng\/mL, and 95.1% for PSA \u22652.0\u00a0ng\/mL, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Our results suggest that novel radiotracers <jats:sup>18<\/jats:sup>F-rhPSMA-7\/7.3 have excellent diagnostic utility as PET imaging agents in BCR of PCa. Further prospective multicenter studies are required to validate these novel tracers in diverse clinical settings with larger patient cohorts and assess their diagnostic accuracy in comparison to the PSMA ligands in current clinical practice.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005641","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:10Z","timestamp":1737676810000},"page":"e323-e330","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Utility of Novel Radiohybrid PSMA Ligands in PET Imaging of Biochemical Recurrence of Prostate Cancer\u2014A Systematic Review and Meta-analysis"],"prefix":"10.1097","volume":"50","author":[{"given":"Kunal Ramesh","family":"Chandekar","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5318-6644","authenticated-orcid":false,"given":"Swayamjeet","family":"Satapathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrasekhar","family":"Bal","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"bib1-20250613","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"bib2-20250613","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.15585\/mmwr.mm6941a1","article-title":"Prostate cancer incidence and survival, by stage and race\/ethnicity\u2014United States, 2001\u20132017","volume":"69","author":"Siegel","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"bib3-20250613","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/jcb.10661","article-title":"Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer","volume":"91","author":"Ghosh","year":"2004","journal-title":"J Cell Biochem"},{"key":"bib4-20250613","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.juro.2015.12.025","article-title":"Diagnostic efficacy of (68)gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer","volume":"195","author":"Maurer","year":"2016","journal-title":"J Urol"},{"key":"bib5-20250613","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"bib6-20250613","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.2967\/jnumed.118.222885","article-title":"Bridging the imaging gap: PSMA PET\/CT has a high impact on treatment planning in prostate cancer patients with biochemical recurrence\u2014a narrative review of the literature","volume":"60","author":"Ekmekcioglu","year":"2019","journal-title":"J Nucl Med"},{"key":"bib7-20250613","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/pcan.2016.13","article-title":"PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges","volume":"19","author":"Rowe","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"bib8-20250613","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.apradiso.2012.06.034","article-title":"Comparison of gallium-68 and fluorine-18 imaging characteristics in positron emission tomography","volume":"76","author":"Sanchez-Crespo","year":"2013","journal-title":"Appl Radiat Isot"},{"key":"bib9-20250613","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/RLU.0000000000004430","article-title":"Comparison of 18F-PSMA-1007 PET\/CT with 68Ga-PSMA-11 PET\/CT for initial staging in intermediate- and high-risk prostate cancer","volume":"48","author":"Chandekar","year":"2023","journal-title":"Clin Nucl Med"},{"key":"bib10-20250613","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.nucmedbio.2021.12.005","article-title":"Recent advancements in 18F-labeled PSMA targeting PET radiopharmaceuticals","volume":"106-107","author":"Piron","year":"2022","journal-title":"Nucl Med Biol"},{"key":"bib11-20250613","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2967\/jnumed.119.234922","article-title":"Radiohybrid ligands: a novel tracer concept exemplified by 18F- or 68Ga-labeled rhPSMA inhibitors","volume":"61","author":"Wurzer","year":"2020","journal-title":"J Nucl Med"},{"key":"bib12-20250613","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13550-021-00872-w","article-title":"Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3","volume":"12","author":"Knorr","year":"2022","journal-title":"EJNMMI Res"},{"key":"bib13-20250613","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"bib14-20250613","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"bib15-20250613","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2967\/jnumed.119.234914","article-title":"18F-rhPSMA-7 PET for the detection of biochemical recurrence of prostate cancer after radical prostatectomy","volume":"61","author":"Eiber","year":"2020","journal-title":"J Nucl Med"},{"key":"bib16-20250613","doi-asserted-by":"crossref","first-page":"968","DOI":"10.2967\/jnumed.120.255661","article-title":"Positive predictive value and correct detection rate of 18F-rhPSMA-7 PET in biochemically recurrent prostate cancer validated by composite reference standard","volume":"62","author":"Chantadisai","year":"2021","journal-title":"J Nucl Med"},{"key":"bib17-20250613","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2967\/jnumed.120.260091","article-title":"Detection efficacy of 18F-rhPSMA-7.3 PET\/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment","volume":"62","author":"Rauscher","year":"2021","journal-title":"J Nucl Med"},{"key":"bib18-20250613","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.2967\/jnumed.121.262861","article-title":"18F-rhPSMA-7 PET for the detection of biochemical recurrence of prostate cancer after curative-intent radiation therapy: a bicentric retrospective study","volume":"63","author":"Ilhan","year":"2022","journal-title":"J Nucl Med"},{"key":"bib19-20250613","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/JU.0000000000003493","article-title":"Diagnostic performance and safety of 18F-rhPSMA-7.3 positron emission tomography in men with suspected prostate cancer recurrence: results from a phase 3, prospective, multicenter study (SPOTLIGHT)","volume":"210","author":"Jani","year":"2023","journal-title":"J Urol"},{"key":"bib20-20250613","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"key":"bib21-20250613","doi-asserted-by":"crossref","first-page":"482.e5","DOI":"10.1016\/j.urolonc.2016.05.026","article-title":"Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1\u00a0ng\/ml following prostatectomy: how much information can conventional imaging provide?","volume":"34","author":"Vargas","year":"2016","journal-title":"Urol Oncol"},{"key":"bib22-20250613","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis","volume":"70","author":"Perera","year":"2016","journal-title":"Eur Urol"},{"key":"bib23-20250613","doi-asserted-by":"crossref","first-page":"649171","DOI":"10.3389\/fonc.2021.649171","article-title":"Performance of 18F-DCFPyL PET\/CT imaging in early detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis","volume":"11","author":"Sun","year":"2021","journal-title":"Front Oncol"},{"key":"bib24-20250613","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2967\/jnumed.119.234898","article-title":"Intraindividual comparison of 18F-PSMA-1007 with renally excreted PSMA ligands for PSMA PET imaging in patients with relapsed prostate cancer","volume":"61","author":"Dietlein","year":"2020","journal-title":"J Nucl Med"},{"key":"bib25-20250613","doi-asserted-by":"crossref","first-page":"702","DOI":"10.2967\/jnumed.119.234609","article-title":"Quantitative and qualitative analyses of biodistribution and PET image quality of a novel radiohybrid PSMA, 18F-rhPSMA-7, in patients with prostate cancer","volume":"61","author":"Oh","year":"2020","journal-title":"J Nucl Med"},{"key":"bib26-20250613","doi-asserted-by":"crossref","first-page":"3502389","DOI":"10.1155\/2021\/3502389","article-title":"18F-PSMA-1007 PET in biochemical recurrent prostate cancer: an updated meta-analysis","volume":"2021","author":"Ferrari","year":"2021","journal-title":"Contrast Media Mol Imaging"},{"key":"bib27-20250613","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol"},{"key":"bib28-20250613","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","article-title":"Diagnostic performance of 18F-DCFPyL-PET\/CT in men with biochemically recurrent prostate CANCER: results from the CONDOR phase III, multicenter study","volume":"27","author":"Morris","year":"2021","journal-title":"Clin CANCER Res"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005641","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T12:00:48Z","timestamp":1749816048000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005641","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"2024-10-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}